Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size

Focal Segmental Glomerulosclerosis Treatment Market Analysis

The focal segmental glomerulosclerosis (FSGS) treatment market is expected to register a CAGR of 7.5% over the forecast period.

Although COVID-19 infection primarily affected the lungs, the cause of the nephropathy that developed as a result of COVID-19 infection was unknown because the damage could have been caused by another virus or kidney damage.Glomerular lesions were reported in a minority of patients with COVID-19, with collapsing focal segmental glomerulosclerosis (FSGS), also called COVID-associated nephropathy (COVAN). For instance, according to an article published by UpToDate, in November 2022, COVAN patients will be presented with nephrotic-range proteinuria and acute kidney injury. Similar to HIV-associated nephropathy, COVAN occurred exclusively in Africans, and a high proportion of those tested possessed high-risk APOL1 genotypes. Furthermore, according to an article published by Elsevier in December 2021, patients with focal segmental glomerulosclerosis associated with COVID-19 were treated with corticosteroids and cyclosporine. Hence, only a minority of patients associated with glomerular lesions were affected by COVID-19, and thereby the demand for FSGS treatment was unaffected during the pandemic.

Factors such as the increasing burden of focal segmental glomerulosclerosis (FSGS) and a high focus on developing new treatment options are major factors that are expected to drive growth in the market over the forecast period. For instance, according to an article published by MedSpace in October 2022, FSGS is one of the most common causes of primary glomerular disease in adults. FSGS accounts for 35% of all cases in adults undergoing kidney biopsy for proteinuria evaluation, and up to 80% of subjects in African-American patients.Furthermore, according to an article published by the National Library of Medicine in July 2022, FSGS is a frequently encountered cause of nephrotic syndrome, accounting for 40% of cases in adults and 20% in children. Such an increasing burden of FSGS is expected to drive the growth of the studied market.

In addition, a high focus on developing new treatment options is expected to drive the growth of this market over the forecast period. For instance, in February 2021, Travere Therapeutics, Inc. provided a regulatory update for its sparsentan program in focal segmental glomerulosclerosis (FSGS). The company conducted pre-new drug application interactions with the U.S. FDA in pursuit of an accelerated approval submission in the U.S. following the achievement of the interim proteinuria endpoint in the ongoing Phase 3 DUPLEX Study of sparsentan in FSGS, as well as pre-marketing authorization application interactions with the European Medicines Agency for conditional marketing authorization and accelerated assessment consideration in Europe. Over the next few years, the growth of the market is likely to be driven by efforts to find a new way to treat FSGS.

However, the high cost of dialysis and kidney transplants is expected to hinder market growth.